EP Patent

EP3689344A1 — Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof

Assigned to Milestone Pharmaceuticals Inc · Expires 2020-08-05 · 6y expired

What this patent protects

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeuti…

USPTO Abstract

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

Drugs covered by this patent

Patent Metadata

Patent number
EP3689344A1
Jurisdiction
EP
Classification
Expires
2020-08-05
Drug substance claim
No
Drug product claim
No
Assignee
Milestone Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.